Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis

References

• Pascuzzi RM, Shefner J, Chappell AS, Bjerke JS, Tamura R, Chaudhry V, . A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:266–71.
   PubMed Web of Science ®Google Scholar
• Aggarwal SP, Zinman L, Simpson E, Jackson KE, Pinto H, Kaufman P, . Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:481–8.
   PubMed Web of Science ®Google Scholar
• Lau J, Conwit R, Miller R, Cudkowicz M. Therapeutic trials in amyotrophic lateral sclerosis: past, present, and future. In: Brown RH Jr, Swash M, Pasinelli P, editors. Amyotrophic Lateral Sclerosis, 2nd edn. Boca Raton: Informa Healthcare; 2006. pp. 335–56.
   Google Scholar
• Kasarskis EJ, Scarlata D, Hill R, Fuller C, Stambler N, Cedarbaum JM. A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials. J Neurol Sci. 1999;169:118–25.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Davidson M, Moore D, Gad N, Brandis M, Ringel S, . Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4: 177–85.
   PubMed Web of Science ®Google Scholar
• Jackson CE, Rosenfeld J, Moore DH, Bryan WW, Barohn RJ, Wrench M, . A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients. J Neurol Sci. 2001;191:75–8.
   PubMed Web of Science ®Google Scholar
• Kleopa KA, Sherman M, Neal B, Romano GJ, Heiman-Patterson T. Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci. 1999;164:82–8.
   PubMed Web of Science ®Google Scholar
• Lechtzin N, Rothstein J, Clawson L, Diette GB, Wiener CM. Amyotrophic lateral sclerosis: evaluation and treatment of respiratory impairment. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3:5–13.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, . Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004;63:1364–70.
   PubMed Web of Science ®Google Scholar
• Smith RA, Brooks BR. Treatment of pseudobulbar affect in ALS. Lancet Neurol. 2005;4:270.
   PubMedGoogle Scholar
• Hinken AC, Driscoll LC, Lee K, Pannirselvan M, Hartman JJ, Muci AR, . The fast sketetal tropoinin activator, CK-2017357, reduces muscle fatigue in an in situ model of vascular insufficiency. Presented at the Second Annual Aging Muscle Symposium; September 30, 2010; San Francisco, CA.
   Google Scholar
• Hansen R, Saikali KG, Chou W, Russell A, Chen M, Vijayakumar V, . CK-2017357, a novel activator of fast skeletal muscle, increases isometric force evoked by electrical stimulation of the anterior tibialis muscle in healthy male subjects. Presented at the 40th Annual Meeting of the Society for Neuroscience; November 13, 2010; San Diego, CA.
   Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• Derr RE. Performing exact logistic regression with the SAS® system. Proceedings of the 25th Annual SAS® Users Group International Conference (SUGI 25). 2000; 254–55.
   Google Scholar
• Cochran WG. Some methods of strengthening the common χ2 tests. Biometrics. 1954;10:417–51.
   Web of Science ®Google Scholar
• Armitage P. Tests for linear trends in proportions and frequencies. Biometrics. 1955;11:375–86.
   Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH Jr, Johnson H, Qureshi M, . A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology. 2003;61:456–64.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, . Trial of celecoxib in amyotrophic lateral sclerosis. Annals of Neurology. 2006;60:22–31.
   PubMed Web of Science ®Google Scholar
• Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, . A clinical trial of creatine in ALS. Neurology. 2004;63:1656–61.
   PubMed Web of Science ®Google Scholar
• The National Isometric Muscle Strength (NIMS) Database Consortium. Muscular Weakness Assessment: Use of Normal Isometric Strength Data. Arch Phys Med Rehabil. 1996;77:1251–5.
   PubMed Web of Science ®Google Scholar
• Bello-Haas VD, Florence JM, Kloos AD, Scheirbecker J, Lopate G, Hayes SM, . A randomized controlled trial of resistance exercise in individuals with ALS. Neurology. 2007;68:2003–7.
   PubMed Web of Science ®Google Scholar